araag2/HINT huggingface dataset:
Clinical trial NCT03364608 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: as mdi 90 μg, as mdi 180 µg, proventil 90 μg, proventil 180 μg
SMILES: CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria

          -  Are at least 12 years of age and no older than 65 years

          -  Have stable (for 6 months) physician-diagnosed asthma with historical documentation of
             the diagnosis

          -  Must be receiving 1 of the following required inhaled asthma therapies listed below
             for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low
             to medium doses of ICS (alone or in combination with LABA), used regularly as
             maintenance asthma therapy

          -  Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society
             [ATS]/European Respiratory Society [ERS] acceptability/repeatability criteria

          -  Pre-bronchodilator FEV1 of ≥40 to <90% predicted normal value after withholding SABA
             for ≥6 hours

          -  Confirmed FEV1 reversibility to Ventolin, defined as a post-Ventolin increase in FEV1
             of ≥15%

          -  only 2 reversibility testing attempts are allowed

        Exclusion Criteria:

          -  Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic
             bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or
             bronchopulmonary dysplasia)

          -  Oral corticosteroid use (any dose) within 6 weeks

          -  Current smokers, former smokers with >10 pack-years history, or former smokers who
             stopped smoking <6 months (including all forms of tobacco, e-cigarettes [vaping], and
             marijuana)

          -  Life-threatening asthma as defined as any history of significant asthma episode(s)
             requiring intubation associated with hypercapnia, respiratory arrest, hypoxic
             seizures, or asthma-related syncopal episode(s)

          -  Historical or current evidence of a clinically significant disease

          -  Cancer not in complete remission for at least 5 years

          -  Hospitalized for psychiatric disorder or attempted suicide within 1 year

          -  Unable to abstain from protocol-defined prohibited medications during the study
Clinical trial NCT03365999 (phase 2, status: completed)
Conditions: knee osteoarthritis, blood clot, transfusion related complication, blood loss
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30, P61.3, D50.0, P50.8, P50.9, P50.2, P50.0, P50.1
Drugs: oral tranexamic acid, oral aminocaproic acid
SMILES: NC[C@H]1CC[C@@H](CC1)C(O)=O, NCCCCCC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Age over 18 years

          2. Total replacement of the primary knee due to primary Osteoarthrosis

          3. Two-compartment prosthesis

          4. Unilateral procedure

          5. Cemented prosthesis

          6. Desire to participate voluntarily in the study and signature of informed consent

          7. Pre-operative assessment with result between ASA I, ASA II or ASA III performed and
             annexed in the clinical file either by the Department of Internal Medicine, Cardiology
             or Anesthesiology of our hospital.

          8. Possibility for oral administration of the drug.

        Exclusion Criteria:

          1. History of thrombotic or embolic event in the last 6 months

          2. Clinical history of coagulopathy

          3. Previous surgeries in the knee to intervene

          4. Patients who have received aspirin, platelet or cumarinic antiplatelet agents in the
             week prior to surgery or NSAIDs two days prior to surgery.

          5. History of myocardial infarction, arteriopathy or unstable angina in the 12 months
             prior to surgery.

          6. Those patients whose preoperative assessment corresponds to an ASA IV or the procedure
             is contraindicated in its preoperative assessment.

          7. Total revision knee replacement

          8. Total replacement of tumoral knee

          9. Total bilateral knee replacement

         10. Cognitive deficit

         11. Patients who meet the inclusion criteria but do not wish to participate in the study

         12. Patients with a diagnosis of Terminal Chronic Kidney Disease or with a serum
             creatinine higher than 1.47 mg / dl in the preoperative laboratories.

         13. Patients with inability to ingest the drug orally.

         14. Patients who are pregnant or breast-feeding or who are taking oral contraceptives.

         15. Seizure history

         16. Hypersensitivity to the active substance or to any of the excipients.
Clinical trial NCT03371459 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: as mdi, proventil
SMILES: CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Have stable (for 6 months) physician-diagnosed asthma with historical documentation of
             the diagnosis

          -  Must be receiving 1 of the following required inhaled asthma therapies listed below
             for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low
             to medium doses of ICS (alone or in combination with LABA), used regularly as
             maintenance asthma therapy

          -  Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society
             [ATS]/European Respiratory Society [ERS] acceptability/repeatability criteria

          -  Pre-bronchodilator FEV1 of ≥50 to <80% predicted normal value after withholding SABA
             ≥6 hours

          -  Confirmed FEV1 reversibility to Ventolin, defined as a post-Ventolin increase in FEV1
             of ≥15%

          -  Only 2 reversibility testing attempts are allowed

        Exclusion Criteria:

          -  Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic
             bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or
             bronchopulmonary dysplasia)

          -  Oral corticosteroid use (any dose) within 6 weeks

          -  Received any marketed (eg, omalizumab, mepolizumab, reslizumab) or investigational
             biologic within 3 months or 5 half-lives, whichever is longer, or any other medication
             specifically prohibited by the protocol

          -  Current smokers, former smokers with >10 pack-years history, or former smokers who
             stopped smoking <6 months (including all forms of tobacco, e-cigarettes [vaping], and
             marijuana)

          -  Life-threatening asthma as defined as any history of significant asthma episode(s)
             requiring intubation associated with hypercapnia, respiratory arrest, hypoxic
             seizures, or asthma-related syncopal episode(s)

          -  Historical or current evidence of a clinically significant disease

          -  Cancer not in complete remission for at least 5 years

          -  Hospitalized for psychiatric disorder or attempted suicide within 1 year

          -  Unable to abstain from protocol-defined prohibited medications during the study
Clinical trial NCT03373422 (phase 2, status: terminated)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: bay1128688, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study bay1128688/17472 (akrendo 1) was terminated early on 20 july 2018 due to hepatotoxicity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Women of at least 18 years of age at the time of signing of informed consent

          -  Women with endometriosis confirmed by at least one of the two criteria:

               -  surgery within the last 10 years

               -  imaging within the last 12 months

          -  moderate to severe pelvic pain which will be assessed over a period of 28 days

          -  Willingness to use only ibuprofen as rescue pain medication for
             endometriosis-associated pelvic pain

          -  Willingness to use non-hormonal barrier method for contraception (here
             spermicide-coated condoms) from screening visit until the end of the study (unless
             adequate contraception is achieved by vasectomy of the partner or use of copper
             intrauterine device [IUD] or commitment to abstinence) and refrain from using hormonal
             contraception

        Exclusion Criteria:

          -  Pregnancy or lactation (more than three months since delivery, abortion, or lactation
             before start of treatment) AND no wish for pregnancy during the study

          -  Altered bilirubin metabolism and liver function at Visit 1

          -  Requirement to use pain medications for reasons other than endometriosis

          -  Contraindications to using ibuprofen

          -  Signs of hyperandrogenism

          -  Absence of menstrual cycles and/or abnormal vaginal/genital bleeding

          -  History of hysterectomy, tubal-ligation or bilateral ovariectomy

          -  Uncontrolled thyroid disorder
Clinical trial NCT03379012 (phase 2, status: completed)
Conditions: metastatic renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: testosterone undecanoate and sunitinib or pazopanib
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically proven clear cell renal cell carcinoma;

          2. CT-confirmed metastatic measurable disease;

          3. First-line sunitinib or pazopanib treatment with fatigue;

          4. Low level of testosterone;

        4. Male, 18 years and older; 5. Normal PSA level

        Exclusion Criteria:

          1. Prostate and other cancers history

          2. Hypothyroidism

          3. History of serious cardiac arrhythmia, congestive heart failure, angina pectoris, or
             other severe cardiovascular disease (i.e., New York Heart Association class III or IV)
Clinical trial NCT03381118 (phase 2, status: terminated)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: cytarabine, nivolumab, cytarabine, nivolumab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    unexpected toxicity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of acute myeloid leukemia with the confirmed first or second
             complete remission

          -  ≥ 55 years of age

          -  Not candidates for allogeneic stem cell transplantation as decided by the panel of
             hematologists at the transplant center

          -  Patients with a HLA-haploidentical donor who should be able to provide informed
             consent for peripheral blood apheresis

          -  No severe concurrent illness that limits life expectancy to less than 2 years

        Exclusion Criteria:

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Karnofsky index <70%

          -  Acute promyelocytic leukemia

          -  Other tumor requiring treatment at the time of enrollment

          -  Active or prior documented autoimmune disease requiring systemic treatment

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent
Clinical trial NCT03384966 (phase 2, status: completed)
Conditions: stable coronary artery disease
ICD codes: I25.84, I25.41, I25.42, Z98.61, Q24.5, T46.3X6S, I25.82
Drugs: act-246475, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  1. Signed informed consent prior to any study-mandated procedure.

          -  2. Male and female subjects aged from 18-85 years, inclusive.

          -  3. For women of childbearing potential: Negative urine pregnancy test at Visit 1 and
             at Visit 2 before randomization.

          -  4. Stable CAD defined by the presence of any of the following conditions:

               1. History of CAD with coronary artery stenosis on coronary angiogram ≥50%.

               2. Previously documented myocardial infarction occurring more than 3 months prior to
                  randomization.

          -  5. Antiplatelet background therapy stable for at least 1 month prior to randomization.

          -  6. Body weight ≥ 40.0 kg (88.2 lbs).

        Main Exclusion Criteria:

          -  1. Acute coronary syndrome, percutaneous coronary intervention or any intervention for
             peripheral artery disease within 3 months prior to randomization.

          -  2. Acute ischemic stroke or transient ischemic attack (TIA) within 3 months prior to
             randomization.

          -  3. Active internal bleeding, or medical history of recent (< 1 month) bleeding
             disorders or conditions associated with high risk of bleeding (e.g., clotting
             disturbances, gastrointestinal bleed, hemoptysis).

          -  4. Hemoglobin ≤ 10 g/dL at screening.

          -  5. Loss of at least 250 mL of blood within 3 months of screening.

          -  6. Use of anticoagulants (oral, parenteral) or fibrinolytic therapy within 24 h prior
             to screening (Visit 1).

          -  7. Known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von Willebrand
             disease).

          -  8. Pregnant or breastfeeding women.
Clinical trial NCT03391765 (phase 2, status: terminated)
Conditions: progressive supranuclear palsy (psp)
ICD codes: G23.1
Drugs: abbv-8e12, placebo solution for iv infusion on day 15
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was prematurely discontinued because the program for progressive supranuclear palsy
    was discontinued due to lack of efficacy.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participant completed the 52-week treatment period in Study M15-562 (NCT02985879)

          -  In the opinion of the investigator, the participant was compliant during participation
             in Study M15-562 (NCT02985879)

          -  Participant has an identified, reliable, study partner (e.g., caregiver, family
             member, social worker, or friend)

        Exclusion Criteria:

          -  Participants who weigh less than 44 kg (97 lbs) at the time of study entry

          -  Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI)

          -  Participant has any significant change in his/her medical condition that could
             interfere with the subject's participation in the study, could place the subject at
             increased risk, or could confound interpretation of study results

          -  More than 8 weeks have elapsed since the participant received his/her last dose of
             study drug in Study M15-562 (NCT02985879)

          -  Participant is considered by the investigator, for any reason, to be an unsuitable
             candidate to receive ABBV-8E12 or the participant is considered by the investigator to
             be unable or unlikely to comply with the dosing schedule or study evaluations
Clinical trial NCT03393117 (phase 2, status: withdrawn)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: liposomal bupivacaine, bupivacaine, patient-controlled analgesia pump, oral narcotic
SMILES: CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C, CC1=CC(O)=CC(C)=C1Cl, [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
Reason stopped: 
    no accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients scheduled to have a unilateral, immediate breast reconstruction

        Exclusion Criteria:

          -  Pregnant

          -  Concurrent or recent medical condition that could interfere with study participation
             including:

               -  Hepatitis

               -  Alcohol/substance abuse

               -  Uncontrolled psychiatric disorders

               -  Known allergy

               -  Contraindication to amide-type local anesthetics, opioids, or propofol.

          -  Body weight of less than 50 kg

          -  Participated in another study involving an investigational medication within the prior
             30 days

          -  Taking analgesics (i.e., nonsteroidal anti-inflammatory drugs, acetaminophen, or
             opioids), antidepressants, or glucocorticoids within the 3 days before surgery.
Clinical trial NCT03397394 (phase 2, status: terminated)
Conditions: bladder cancer, urothelial carcinoma, metastatic urothelial carcinoma, renal pelvis carcinoma, ureter carcinoma, urinary bladder carcinoma, urethra carcinoma, muscle invasive bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: rucaparib
SMILES: CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3
Reason stopped: 
    efficacy did not meet the continuance criteria and dmc recommended to stop enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Have histologically or cytologically confirmed locally advanced unresectable or
             metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter,
             urinary bladder or urethra)

          -  Received 1 or 2 prior treatment regimens for advanced or metastatic disease

          -  Confirmed radiologic disease progression during or following recent treatment

          -  Mandatory biopsy is required during screening

          -  Measurable disease per RECIST v1.1

          -  Adequate organ function

          -  ECOG 0 or 1

        Exclusion Criteria:

          -  Prior treatment with a PARP inhibitor

          -  Symptomatic and/or untreated CNS metastases

          -  Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption
             of rucaparib
Clinical trial NCT03399669 (phase 2, status: unknown status)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed stage IIIB/IV or recurrent NSCLC with activating EGFR
             mutation in exon 18 through exon 21 except T790M

          -  Patients who achieved complete/partial response more than 4 months or stable disease
             more than 6 months with first-line or second line gefitinib

          -  Patients who experience disease progression by RECIST 1.1 criteria

          -  Age ≥ 18years

          -  ECOG performance status of 0 to 2

          -  Adequate organ function as evidenced by the following; Absolute neutrophil count > 1.5
             x 109/L; platelets > 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or ALT < 5 UNL,
             CCr ≥ 50mL/min

          -  Baseline adverse event of gefitinib ≤ Grade 2

          -  Written informed consent form

        Exclusion Criteria:

          -  Prior treatment with EGFR TKI

          -  Patients who required dose reduction of gefitinib

          -  Surgery undertaken less than 4 weeks before the study

          -  Localized radiotherapy unless completed more than 2 weeks before the study

          -  Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or
             arrhythmia

          -  Pregnant or nursing women ( Women of reproductive potential have to agree to use an
             effective contraceptive method (hormonal or barrier methods))

          -  Uncontrolled symptomatic brain metastasis

          -  Prior history of malignancy within 5 years from study entry except for adequately
             treated basal cell or squamous cell skin cancer or in situ cervical cancer,
             well-treated thyroid cancer

          -  Concomitant use of CYP3A4 inducers/inhibitors

          -  Prolonged QT interval in ECG (QTc >450 msec)

          -  Patients who cannot take a medicine orally or who have a gastrointestinal absorption
             disorder
Clinical trial NCT03400163 (phase 2, status: completed)
Conditions: non-alcoholic steatohepatitis
ICD codes: K75.81
Drugs: bms-986036, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male or female between 21 and 75 years old

          -  Body Mass Index (BMI) of 25 or more

        Exclusion Criteria:

          -  Chronic Liver disease other than NASH

          -  Uncontrolled diabetes

          -  Any major surgery within 6 weeks of screening

          -  Unable to self-administer under the skin injections

          -  Any bone trauma, fracture or bone surgery within 8 weeks of screening
Clinical trial NCT03404115 (phase 2, status: completed)
Conditions: dry eye syndrome
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: reproxalap ophthalmic solution (0.25%), reproxalap ophthalmic solution (0.1%), vehicle ophthalmic solution
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Be at least 18 years of age of either gender and any race;

          -  Have a reported history of dry eye for at least 6 months prior to Visit 1;

          -  Have a history of use or desire to use eye drops for dry eye symptoms within 6 months
             of Visit 1;

        Exclusion Criteria:

          -  Have any clinically significant slit lamp findings at Visit 1 that may include active
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active
             ocular allergies that require therapeutic treatment, and/or in the opinion of the
             investigator may interfere with study parameters;

          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active
             ocular inflammation at Visit 1;

          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses
             during the study;

          -  Have used any eye drops within 2 hours of Visit 1;

          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the
             last 12 months;

          -  Have used cyclosporine 0.05% or lifitigrast 5.0% ophthalmic solution within 90 days of
             Visit 1;

          -  Have any planned ocular and/or lid surgeries over the study period or any ocular
             surgery within 6 months of Visit 1;

          -  Be using or anticipate using temporary punctal plugs during the study that have not
             been stable within 30 days of Visit 1;